Provided by Tiger Trade Technology Pte. Ltd.

Esperion Therapeutics

3.74
+0.573018.08%
Volume:10.89M
Turnover:38.99M
Market Cap:894.81M
PE:-6.99
High:3.75
Open:3.28
Low:3.28
Close:3.17
52wk High:3.94
52wk Low:0.6925
Shares:239.06M
Float Shares:237.00M
Volume Ratio:4.01
T/O Rate:4.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5358
EPS(LYR):-0.2764
ROE:97.76%
ROA:-5.42%
PB:-1.98
PE(LYR):-13.54

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's

Reuters
·
Yesterday

Esperion Therapeutics Initiated at Overweight by Piper Sandler

Dow Jones
·
Yesterday

Piper Sandler Initiates Coverage on Esperion Therapeutics With Overweight Rating

MT Newswires Live
·
Yesterday

BUZZ-Esperion gains after Piper Sandler initiates with 'overweight' rating

Reuters
·
Yesterday

Esperion initiated with an Overweight at Piper Sandler

TIPRANKS
·
Yesterday

U.S. RESEARCH ROUNDUP-Air Products, Hanover Insurance, Kinsale Capital

Reuters
·
Yesterday

Esperion Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $9

THOMSON REUTERS
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-IES Holding, Eli Lilly, Alphabet

Reuters
·
Nov 22

BRIEF-Esperion Partner Otsuka Launches Nexletol In Japan

Reuters
·
Nov 21

Esperion Receives $90 Million Payment as Otsuka Launches NEXLETOL in Japan

Reuters
·
Nov 21

Esperion Partner Otsuka Launches Nexletol® in Japan for the Treatment of Hypercholesterolemia

THOMSON REUTERS
·
Nov 21

Esperion Therapeutics: Under Agreement, Esperion Will Receive $90 Mln in a Near Term Payment as a Result of the Recent Otsuka Achievements

THOMSON REUTERS
·
Nov 21

Esperion Therapeutics: Also Eligible to Receive Additional Sales Milestone Payments Based on Total Net Sales Achievements by Otsuka in Japan

THOMSON REUTERS
·
Nov 21

Esperion Therapeutics Says Health Canada Grants Marketing Approval for Nilemdo

MT Newswires Live
·
Nov 18

Health Canada Approves Esperion’s NILEMDO for LDL-Cholesterol Reduction in At-Risk Canadians

Reuters
·
Nov 18

Esperion Therapeutics Inc -Commercial Launch for Nilemdo Is Expected in Q2 2026

THOMSON REUTERS
·
Nov 18

HLS Therapeutics Inc - Commercial Launch Expected in Q2 2026

THOMSON REUTERS
·
Nov 18

Esperion Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer John B. Harlow Jr

Reuters
·
Nov 18

Stock Track | Esperion Therapeutics Soars 5.26% as New Data Shows NEXLETOL Reduces Cardiovascular Events and Blood Clots

Stock Track
·
Nov 10

Esperion Reports Bempedoic Acid Cuts Major Cardiovascular Events and Venous Thromboembolism in CLEAR Outcomes Study

Reuters
·
Nov 10